Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib versus pazopanib plus gemcitabine for relapsed or metastatic uterine leiomyosarcoma or other uterine tumors
2012-003810-15Phase 2Terminated
- Sponsor
- North Eastern German Society of Gynecological Oncology
- Start
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in uterine leiomyosarcoma (uLMS), endometrial carcinosarcoma and uterine cancer comparing Pazopanib with Pazopanib + Gemedac (2 arms). Primary endpoints: 6-month progression-free survival rate and Progression-free survival. Started Jul 2013; status: terminated.
02
Drugs
pazopanibGemedac
03
Conditions
uterine leiomyosarcoma (uLMS)endometrial carcinosarcomauterine cancer
Beyond the preview
Go deeper on 2012-003810-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003810-15.